{"id":"ib1001","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IB1001 utilizes IntraBio's proprietary intrabone delivery platform to administer biologics or small molecules directly into bone tissue, potentially bypassing systemic circulation and achieving high local concentrations. This approach may enhance therapeutic efficacy while reducing systemic exposure and associated toxicities for bone-related or hematologic conditions.","oneSentence":"IB1001 is an intrabone injection therapy designed to deliver therapeutic agents directly into the bone marrow microenvironment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:27.351Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in development)"}]},"trialDetails":[{"nctId":"NCT07221292","phase":"PHASE3","title":"Pivotal Study of N-acetyl-L-leucine for CACNA1A","status":"NOT_YET_RECRUITING","sponsor":"IntraBio Inc","startDate":"2026-09-01","conditions":"CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2","enrollment":60},{"nctId":"NCT03759678","phase":"PHASE2","title":"N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)","status":"TERMINATED","sponsor":"IntraBio Inc","startDate":"2020-01-08","conditions":"Ataxia Telangiectasia","enrollment":17},{"nctId":"NCT06673056","phase":"PHASE3","title":"A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)","status":"ACTIVE_NOT_RECRUITING","sponsor":"IntraBio Inc","startDate":"2025-03-18","conditions":"Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)","enrollment":60},{"nctId":"NCT05163288","phase":"PHASE3","title":"A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C","status":"RECRUITING","sponsor":"IntraBio Inc","startDate":"2022-06-30","conditions":"Niemann-Pick Disease, Type C","enrollment":53},{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT03759665","phase":"PHASE2","title":"N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)","status":"COMPLETED","sponsor":"IntraBio Inc","startDate":"2019-06-07","conditions":"GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease","enrollment":30},{"nctId":"NCT03759639","phase":"PHASE2","title":"N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)","status":"COMPLETED","sponsor":"IntraBio Inc","startDate":"2019-09-04","conditions":"Niemann-Pick Disease, Type C","enrollment":33},{"nctId":"NCT00768287","phase":"PHASE2, PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2009-01","conditions":"Hemophilia B","enrollment":77},{"nctId":"NCT01271868","phase":"PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B","status":"TERMINATED","sponsor":"Medexus Pharma, Inc.","startDate":"2010-11","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT02048111","phase":"PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B","status":"WITHDRAWN","sponsor":"Cangene Corporation","startDate":"2014-03","conditions":"Hemophilia B","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["N-Acetyl-L-Leucine","Recombinant factor IX (rFIX)","IXINITY","Recombinant factor IX"],"phase":"phase_3","status":"active","brandName":"IB1001","genericName":"IB1001","companyName":"IntraBio Inc","companyId":"intrabio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IB1001 is an intrabone injection therapy designed to deliver therapeutic agents directly into the bone marrow microenvironment. Used for Multiple myeloma (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}